Match!
Shigeru Nakajima
19Publications
6H-index
81Citations
Publications 19
Newest
#1Takashi Miyazaki (YCU: Yokohama City University)H-Index: 4
#2Jun Shirakawa (YCU: Yokohama City University)H-Index: 16
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 13 authors...
Source
#1Masahiko TakaiH-Index: 9
#2Masashi IshikawaH-Index: 7
Last.Ikuro MatsubaH-Index: 14
view all 35 authors...
Background: Sitagliptin, the first dipeptidyl peptidase-4 inhibitor, has demonstrated efficacy and safety as monotherapy and as add-on therapy to oral antidiabetic agents or insulin. However, there have been few reports about sitagliptin in elderly patients. The ASSIST-K observational study was performed in patients with type 2 diabetes mellitus (T2DM) receiving sitagliptin as add-on therapy to insulin. Changes of hemoglobin A1c (HbA1c), body weight, and the estimated glomerular filtration rate ...
Source
#1Kotaro IemitsuH-Index: 5
#2Takehiro KawataH-Index: 10
Last.Ikuro MatsubaH-Index: 14
view all 34 authors...
Background: Sodium glucose cotransporter 2 (SGLT2) inhibitors achieve good glycemic control in patients with type 2 diabetes, as well as reducing body weight and blood pressure. However, no large-scale clinical studies of SGLT2 inhibitors have been performed in Japan. The ASSIGN-K study investigated the efficacy and safety of ipragliflozin, a selective SGLT2 inhibitor, in routine clinical practice. Methods: ASSIGN-K was an investigator-initiated, multicenter, prospective observational study of i...
1 CitationsSource
#1Ikuro MatsubaH-Index: 14
#2Kotaro IemitsuH-Index: 5
Last.Yasuo Terauchi (Yokohama City University Medical Center)H-Index: 58
view all 30 authors...
Background: Dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors are frequently used to treat type 2 diabetes. However, there have been no direct comparisons of these antidiabetic drugs in Japanese patients with type 2 diabetes. Methods: We retrospectively assessed the effects of treatment with sitagliptin (a dipeptidyl peptidase-4 inhibitor) for 24 weeks in the ASSET-K study or treatment with ipragliflozin (a sodium-glucose cotransporter-2 inhibitor) for 24 weeks in t...
Source
#1Rika Sakamoto (Yokohama City University Medical Center)H-Index: 2
#2Tadashi Yamakawa (Yokohama City University Medical Center)H-Index: 24
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 19 authors...
Objectives Excessively short and long sleep durations are associated with type 2 diabetes, but there is limited information about the association between sleep quality and diabetes. Accordingly, the present study was performed to investigate this relationship. Materials and methods The subjects were 3249 patients with type 2 diabetes aged 20 years or older. Sleep quality was assessed by using the Pittsburgh Sleep Quality Index (PSQI). A higher global PSQI score indicates worse sleep quality, and...
8 CitationsSource
Background: Sitagliptin was the first dipeptidyl peptidase-4 (DPP-4) inhibitor approved in Japan. Its efficacy and safety have been demonstrated, both as monotherapy and in combination with oral antidiabetic agents or insulin. However, reduction of hemoglobin A1c (HbA1c) by sitagliptin is insufficient in some patients. Therefore, data from an observational study of sitagliptin as add-on therapy to insulin in patients with type 2 diabetes (ASSIST-K) were used to conduct factor analysis of the 12-...
Source
#1Masayo Kimura (YCU: Yokohama City University)H-Index: 2
#2Yoshinobu Kondo (YCU: Yokohama City University)H-Index: 6
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 8 authors...
Background: Low-carbohydrate diets have been shown to effectively improve the metabolic status of patients with type 2 diabetes mellitus. However, patients may find it challenging to maintain a strict low-carbohydrate diet. The objective of this study was to determine if a one-meal, low-carbohydrate diet is as effective in improving metabolic status as a conventional, energy-restricted diet among patients with type 2 diabetes mellitus. Methods: In this 12-week randomized controlled study, the pr...
3 CitationsSource
#1Kotaro IemitsuH-Index: 5
#2Takehiro KawataH-Index: 10
Last.Ikuro MatsubaH-Index: 14
view all 34 authors...
Background: Ipragliflozin is a selective sodium glucose co-transporter 2 inhibitor. The ASSIGN-K study is investigating the efficacy and safety of ipragliflozin for type 2 diabetes mellitus (T2DM) in the real-world clinical setting. Methods: Japanese T2DM patients with inadequate glycemic control despite diet and exercise with/without pharmacotherapy were enrolled in an investigator-driven, multicenter, prospective, observational study examining the efficacy and safety of ipragliflozin treatment...
1 CitationsSource
#1Kazutaka AokiH-Index: 15
#2Mieko NagakuraH-Index: 2
Last.Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 11 authors...
Background: Patients with type 2 diabetes mellitus often take multiple anti-diabetic drugs for a long period. Fixed dose combination (FDC) therapy is expected to improve drug adherence for patients with diabetes. The effect of switching from a loose dose combination (LDC) regimen to an FDC regimen at equivalent dosage on glycemic control has not been evaluated fully. Therefore, we investigated the effect of switching from LDC to FDC at equivalent dosage for 6 months on glycemic control in Japane...
2 CitationsSource
#1Takehiro KawataH-Index: 10
#2Takashi IizukaH-Index: 3
Last.Ikuro MatsubaH-Index: 14
view all 34 authors...
Background: Ipragliflozin, a sodium-glucose transporter 2 inhibitor, was administered to patients with type 2 diabetes mellitus for 24 weeks to evaluate its effect on glycemic control and body composition. Methods: This was an investigator-initiated multicenter prospective intervention study in which ipragliflozin (50 mg) was administered once daily and glycemic control, blood pressure, body weight (BW), body composition (measured by a biological impedance method), the lipid profile, and adverse...
2 CitationsSource
12